home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences

Search

 
  MOLECULAR DIVERSITY  
  December 05, 2000

Biotechnology

 
     
  Cambridge Healthtech Institute, San Diego, California
February 12-14, 2001


Combinatorial chemistry is now well established as a powerful tool for rapidly providing highly diverse compounds for hit discovery and for more focused lead optimization. Over the years, combichem researchers have become more realistic about the limitations of the technology, with experience teaching that improvements and enhancements are still required and possible. This conference will showcase a variety of topics including ways that library design and diversity assessment can be used to better match a library to biological targets, as well as more efficient means of design, synthesis, testing, and analysis. In addition, the experiences and research of end-users and those involved with the production of compounds entering clinical trials will be presented. Plan now to participate in this meeting, which offers you a time-efficient means of keeping up with the latest developments and understanding as presented by your experienced colleagues.

 
 
Organized by: Cambridge Healthtech Institute
Invited Speakers: Dr. D. Benjamin Borson, Fleister, Dubb, Meyer & Lovejoy, LLP
Dr. Valery Alakhov, Supratek Pharma, Inc.
Dr. Nigel R.A. Beeley, Arena Pharmaceuticals Inc.
Dr. D. Dunn, Pharmacopeia, Inc.
Dr. Adam Golebiowski, Procter & Gamble Pharmaceuticals
Dr. Burt Goodman, Molecumetics
Dr. Erich L. Grimm, Merck Frosst Centre for Therapeutic Research
Dr. Thomas F. Hendrickson, Agouron Pharmaceuticals, Inc.
Dr. Richard A. Houghten, Torrey Pines Institute for Molecular Studies
Dr. Duncan B. Judd, GlaxoWellcome Medicines Research Centre UK
Dr. Kevin Koch, Array BioPharma
Mr. Paul Labute, Chemical Computing Group Inc.
Dr. Roger Lahana, Synt:em, Inc.
Dr. Christian Lemmen, DuPont Pharmaceuticals Research Labs
Dr. Victor S. Lobanov, 3-Dimensional Pharmaceuticals, Inc.
Dr. David R. Lowis, Tripos, Inc.
Dr. Chester A. Metcalf III, ARIAD Pharmaceuticals, Inc.
Dr. Adnan Mjalli, TransTech Pharma, Inc.
Dr. Isabelle Morize, Aventis Pharmaceuticals
Dr. Dora M. Schnur, Bristol-Myers Squibb Company
Dr. Daniel Sem, Triad Therapeutics, Inc.
Dr. Duane L. Venton, University of Illinois at Chicago
Dr. Dirk Vetter, Graffinity Pharmaceuticals Design Gmbh
Dr. Edward A. Wintner, NeoGenesis, Inc.
Dr. Liqun Yang, Glaxo Wellcome R&D

 
Deadline for Abstracts: January 5, 2001
 
Registration: Available on-line
E-mail: jlaakso@healthtech.com
 
  Posted by:   Jennifer Laakso  
Host: wks217.healthtech.com
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2001 HUM-MOLGEN. All rights reserved. Liability and Copyright.